Furthermore, fewer injections might facilitate treatment initiation in patients with type 2 diabetes who have not previously taken insulin, by reducing clinical inertia and promoting better acceptance of insulin therapy (4). This evidence concerns the gene INS and type 2 diabetes mellitus.